CN104356059B - Trans cvclohexvl alkyl amide compound containing halogenated pyridyl and purposes - Google Patents

Trans cvclohexvl alkyl amide compound containing halogenated pyridyl and purposes Download PDF

Info

Publication number
CN104356059B
CN104356059B CN201410635589.2A CN201410635589A CN104356059B CN 104356059 B CN104356059 B CN 104356059B CN 201410635589 A CN201410635589 A CN 201410635589A CN 104356059 B CN104356059 B CN 104356059B
Authority
CN
China
Prior art keywords
compound
present
purposes
compound containing
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201410635589.2A
Other languages
Chinese (zh)
Other versions
CN104356059A (en
Inventor
郭章华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Medical College filed Critical Zhejiang Medical College
Priority to CN201410635589.2A priority Critical patent/CN104356059B/en
Publication of CN104356059A publication Critical patent/CN104356059A/en
Application granted granted Critical
Publication of CN104356059B publication Critical patent/CN104356059B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the drug world relevant to thrombotic diseases.Specifically, the present invention relates to a class containing PAR 1 antagonist of halogenated pyridyl isostructural trans cyclohexane amide structure, its preparation method and their application in preparation treatment thrombotic diseases medicine.Wherein, R is selected from C1‑C3Alkyl, F, Cl, Br, I substituent.

Description

Trans cvclohexvl alkyl amide compound containing halogenated pyridyl and purposes
Technical field
The present invention relates to the drug world relevant to thrombus disease.Specifically, the present invention relates to thrombotic diseases is had One class of therapeutic action contains PAR-1 antagonist and the preparation side thereof of halogenated pyridyl isostructural trans cyclohexane amide structure Method, containing they pharmaceutical composition and in purposes pharmaceutically.
Background technology
Proteinase activated receptors 1 (Protease Activated Acceptor-1, PAR-1) is the anti-blood found recently The novel targets of platelet class antithrombotic reagent.Proteinase activated receptors 1 is again thrombin receptor, after fibrin ferment is activated by coagulation cascade In blood platelet thus activate blood platelet by PAR-1 receptor acting, cause platelet aggregation thus cause thrombus and blood coagulation.PAR- Rich in platelet component in 1 thrombus caused, it it is the main reason of arterial thrombus.PAR-1 antagonist can block thrombin activation Blood platelet, thus interruption artery thrombosis, may be used for treating acute coronary artery disease (Acute Coronary Syndrome).Several PAR-1 inhibitor has been had to be in clinical research (Chackalamannil S., Thrombin Receptor(Protease Activated Receptor-1)Antagonists as Potent Antithrombotic Agents with Strong Antiplatelet Effects, J.Med.Chem., 2006,49 (18), 5389-5403).
The medicine being traditionally used for preventing and treating thrombotic diseases is divided three classes.The first kind is anticoagulation class, is divided into direct blood coagulation Enzyme inhibitor and indirect thrombin inhibitor, such medicine suppresses thrombus shape by the different links acting on coagulation cascade Become, there are the various thrombotic effects of suppression, such as vitamin K antagon and Xa factor inhibitor etc.;Equations of The Second Kind is that anti-blood is little Plate class, such as COX-1 inhibitor and adp receptor antagonist etc., such medicine is mainly used in preventing and treating arterial thrombus;3rd class is fiber Protein dissolution agent, is mainly used in lysed blood the fibrin formed.
Mostly antiplatelet drug is traditional arterial thrombus protective agents, such as clopidogrel and aspirin etc..These medicines The shortcoming of thing is that bleeding risk is bigger.And as the PAR-1 antagonist of newfound antiplatelet class antithrombotic reagent, then have Having less bleeding risk, therefore this compounds can be as the most promising medicine for the treatment of arterial thrombus.
The invention discloses the class PAR-1 antagonist containing halogenated pyridyl isostructural trans cyclohexane amide structure, They may be used for preparing the medicine of anti-arterial thrombus disease.
Summary of the invention
It is an object of the present invention to provide a kind of have good anti-thrombosis activity have compounds of formula I and Its pharmaceutically acceptable salt.
It is a further object to provide preparation and there is compounds of formula I and pharmaceutically acceptable salt thereof Method.
It is also another object of the present invention to provide containing compounds of formula I and pharmaceutically acceptable salt as having Effect composition, and one or more pharmaceutically acceptable carriers, excipient or the Pharmaceutical composition of diluent, and in treatment Application in terms of arterial thrombus.
In conjunction with the purpose of the present invention, present invention is specifically described.
The present invention has compounds of formula I and has a following structural formula:
Wherein, R is selected from C1-C3Alkyl, F, Cl, Br, I substituent.
Further, preferably following have compounds of formula I,
Further, preferably following have compounds of formula I,
Compound of formula I of the present invention synthesizes by the following method:
Compound II and compound III reacts in the presence of condensing agent, obtains product I.Described condensing agent selected from DCC (N, N '-dicyclohexyl carbodiimide), EDC (N-ethyl-N '-dimethylamino carbodiimides), CDI (carbonyl dimidazoles).
The pharmaceutically acceptable salt of compound of formula I of the present invention, includes, but are not limited to and various inorganic acids such as salt The salt that acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid etc. are formed, also includes and various organic acids such as acetic acid, butanedioic acid, maleic acid, apple The salt that tartaric acid and various amino acid etc. are formed.
Compound of Formula I of the present invention has the antagonism of PAR-1, can be used for preparing antithrombotic as active ingredient The medicine of aspect.The activity of compound of Formula I of the present invention is verified by external model.
The compound of Formula I of the present invention is effective in comparatively wide dosage range.The dosage that such as every day takes is about In the range of 1mg-500mg/ people, it is divided into once or is administered for several times.The actual dosage taking compound of Formula I of the present invention can be by curing Take root and determine according to relevant situation.These situations include: the condition of patient, method of administration, the age, body weight, right The individual reaction of medicine, the order of severity etc. of symptom.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that following embodiment is only for Illustrate, and be not intended to limit the present invention.Those skilled in the art all should according to the various changes that the teachings of the present invention is made Within the protection domain required by the application claim.
The preparation of embodiment 1 compound I-1
Raw material: commercially available or self-control.
In one 100mL round-bottomed flask, add 1.84g (10mmol) compound II, 1.98g (10mmol) compound III- 1 and the 20mL THF being dried, gained mixture stirs under ice-water bath cools down, and after adding 2.48g (12mmol) DCC, continues in room It is stirred overnight under temperature.TLC display reaction completes.
Reactant mixture pours in frozen water, stirring, extracts with the dichloromethane of 50mL × 3, merges extraction organic phase, uses Saturated aqueous common salt washs, and anhydrous sodium sulfate is dried, and boils off solvent on a rotary evaporator, and the residue column chromatography obtained purifies, Obtain product I-1, white solid, ESI-MS, m/z=365 ([M+H]+)。
Embodiment 2-8
With reference to the method for embodiment 1, synthesize the following compounds with formula I.
The suppression test of embodiment 9 extracorporeal platelet aggregation
In 96 orifice plates, the platelet aggregation induced at TRAP (Glycoprotein) concentrates the pharmacology carrying out material Test.Syringe is previously added the sodium citrate solution of 3.13%, the then blood of suction 20mL healthy volunteer, Under 1500g centrifugal 20 minutes, will be enriched in hematoblastic blood plasma (PRP) separate and with 1 μ L PGE1 solution (500 μ g/mL's Ethanol solution) amount of/mL PRP processes.After at room temperature hatching 5 minutes, it is centrifuged under 1200g 20 minutes to remove Leucocyte-removing.PRP without leucocyte is transferred to 5mL/ part in the PP pipe of 15mL in batches, and centrifugal under 3600g make blood Platelet precipitates.Then, drain upper plasma, the pellet platelets deriving from 5mL PRP is suspended in 1mL Tyrode again (120mM NaCl, 2.6mM KCl, 12mM NaHCO3, 0.39mM NaH2PO4, 10mM HEPES, 0.35%BSA, 5.5mM Portugal Grape sugar, pH=7.4) in, and regulate the platelet count to 3 × 105/ μ L with Tyrode.This for 13mL cell suspension is used The 10mM CaCl of 866 μ L2Solution processes, and is drawn in 96 orifice plates, in the hole of 96 orifice plates with the amount of every hole 120 μ L Add 15 μ L materials to be tested in advance.At room temperature dark is hatched 30 minutes, add 15 μ L TRAP solution (70-100 μM) As activator, vibrate 20 minutes at 37 DEG C in SpectraMax, under 650nm, note down dynamics, calculate negative control (tyrode/DMSO) and the TG-AUC of positive control (15 μ L activators/DMSO), and difference is set to 100%.By to be measured Examination compound aspirates with the form of serial dilution thing, is measured in duplicate, the same AUC measuring each material concentration, meter Calculate AUC compared with the control and suppress %.IC is calculated according to 4 parametric equations by nonlinear regression analysis by this suppression %50Value. Following table gives result.
Compound The suppression IC of platelet aggregation50(μM)
Compound I-1 0.9
Compound I-2 4.1
Compound I-3 3.5
Compound I-4 3.2
Compound I-5 2.0
Compound I-6 4.7
Compound I-7 4.2
Compound I-8 3.8
As can be seen from the above table, the compound of the present invention all shows inhibitory action in platelet aggregation test.

Claims (3)

1. following compounds,
2. compound described in claim 1, selected from following compounds:
3. compound of Formula I defined in any one of claim 1-2 and pharmaceutically acceptable salt preparation treatment blood Purposes in terms of bolt medicine.
CN201410635589.2A 2014-11-02 2014-11-02 Trans cvclohexvl alkyl amide compound containing halogenated pyridyl and purposes Expired - Fee Related CN104356059B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410635589.2A CN104356059B (en) 2014-11-02 2014-11-02 Trans cvclohexvl alkyl amide compound containing halogenated pyridyl and purposes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410635589.2A CN104356059B (en) 2014-11-02 2014-11-02 Trans cvclohexvl alkyl amide compound containing halogenated pyridyl and purposes

Publications (2)

Publication Number Publication Date
CN104356059A CN104356059A (en) 2015-02-18
CN104356059B true CN104356059B (en) 2016-08-24

Family

ID=52523396

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410635589.2A Expired - Fee Related CN104356059B (en) 2014-11-02 2014-11-02 Trans cvclohexvl alkyl amide compound containing halogenated pyridyl and purposes

Country Status (1)

Country Link
CN (1) CN104356059B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057868A1 (en) * 2004-11-29 2006-06-01 Eli Lilly And Company Antithrombotic diamides
CN104072438A (en) * 2014-07-23 2014-10-01 张远强 Di-alkoxy substituted tetrazole acetophenone compound, as well as preparation method and application thereof
CN104086503A (en) * 2014-07-23 2014-10-08 张远强 PAR (Protease Activated Receptor)-1 antagonist and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057868A1 (en) * 2004-11-29 2006-06-01 Eli Lilly And Company Antithrombotic diamides
CN104072438A (en) * 2014-07-23 2014-10-01 张远强 Di-alkoxy substituted tetrazole acetophenone compound, as well as preparation method and application thereof
CN104086503A (en) * 2014-07-23 2014-10-08 张远强 PAR (Protease Activated Receptor)-1 antagonist and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
N-Acyl-N0-arylpiperazines as negative allosteric modulators of mGlu1:Identification of VU0469650, a potent and selective tool compound with CNS exposure in rats;Kimberly M.Lovell等;《Bioorganic & Medicinal Chemistry Letters》;20131231;第23卷;第3713-3718页 *
S. P. Webster et al. Discovery and biological evaluation of adamantly amide 11β-HSD1 inhibitors;S. P. Webster et al.;《Bioorg. Med. Chem. Lett.》;20070225;pp2838-2843 *

Also Published As

Publication number Publication date
CN104356059A (en) 2015-02-18

Similar Documents

Publication Publication Date Title
CN104072436A (en) Para-position substituted tetrazole acetophenone compound, preparation method and application
CN104529927B (en) One class is containing oxadiazoles sulfoxide compound, the Preparation Method And The Use of halogeno-benzene
CN104098520A (en) Phenyl triazole schiff base compound as well as preparation method and application thereof
CN104086503B (en) PAR-1 antagonist and uses thereof
CN104072439A (en) Halogen-substituted four nitrogen azole acetophenone compound,preparation method and application thereof
CN104072437A (en) Disubstituted tetrazole acetophenone compound and preparation method and use thereof
CN104086500B (en) A kind of PAR-1 antagonist and uses thereof
CN104356059B (en) Trans cvclohexvl alkyl amide compound containing halogenated pyridyl and purposes
CN104356058B (en) Trans cvclohexvl alkyl amide compound containing alkoxy pyridines and purposes
CN104356060B (en) The trans cvclohexvl alkyl amide compound of 2-pyridine radicals and purposes
CN104326974B (en) The trans cvclohexvl alkyl amide compound of 4 pyridine radicals and purposes
CN104356094B (en) Trans cvclohexvl alkyl amide compound, its preparation method and in purposes pharmaceutically
CN104086496B (en) A kind of antithrombotic compound, Preparation Method And The Use
CN104356093B (en) Trans cvclohexvl alkyl amide compound containing halogenophenyl and purposes
CN104447624B (en) The trans cvclohexvl alkyl amide compound of nitrile group-containing phenyl and purposes
CN104496924B (en) Halobenzene diene tetrazole compound, Preparation Method And The Use
CN104356095B (en) The trans cvclohexvl alkyl amide compound of alkoxyl phenyl replacement and purposes
CN104496925B (en) Diene tetrazole compound, Preparation Method And The Use
CN104513212B (en) Oxadiazoles sulfoxide compound, the Preparation Method And The Use of one class nitrobenzene-containing
CN104387341B (en) A kind of trans cvclohexvl alkyl amide compound and purposes
CN104496927B (en) Diene tetrazole halobenzene compounds, Preparation Method And The Use
CN104496923B (en) Oil of mirbane diene tetrazole compound, Preparation Method And The Use
CN104496922B (en) Itrile group benzene diene tetrazole compound, Preparation Method And The Use
CN104478819B (en) Diene tetrazole amino benzenes compounds, Preparation Method And The Use
CN104529930B (en) One class nitrile group-containing Ben oxadiazole sulfoxide compound, Preparation Method And The Use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160824

Termination date: 20171102